ALW-II-41-27 5 mg | 99.52%
TargetMol
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
More Information Supplier PageALW-II-41-27
Search Results
AG-494 5 mg | 98.90%
TargetMol
AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.
More Information Supplier PageAG-494
ML327 1 mg | 99.48%
TargetMol
ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
More Information Supplier PageML327
ML327 5 mg | 99.48%
TargetMol
ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
More Information Supplier PageML327
ML327 10 mg | 99.48%
TargetMol
ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
More Information Supplier PageML327
Cefquinome sulfate 100 mg | Purity Not Available
TargetMol
Cefquinome Sulfate is a semisynthetic, broad-spectrum, fourth-generation aminothiazolyl cephalosporin with antibacterial activity.
More Information Supplier PageCefquinome sulfate
Cefquinome sulfate 200 mg | Purity Not Available
TargetMol
Cefquinome Sulfate is a semisynthetic, broad-spectrum, fourth-generation aminothiazolyl cephalosporin with antibacterial activity.
More Information Supplier PageCefquinome sulfate
AM966 2 mg | 99.49%
TargetMol
AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.
More Information Supplier PageAM966
AM966 5 mg | 99.49%
TargetMol
AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.
More Information Supplier PageAM966
AM966 10 mg | 99.49%
TargetMol
AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.
More Information Supplier PageAM966